- A Pre-Emptive Strike at Mantle Cell LymphomaJanuary 01, 2010 | Peter Johnson, MD
While the results of treatment for germinal center lymphomas have been steadily improving, the natural history of mantle cell lymphoma (MCL) has been more difficult to influence, and the median survival has remained three to five years in most series.
- Adding MicroRNA-29 to the Tumor Suppressor FamilyJanuary 01, 2010 | Diane Krause, MD, PhD
MicroRNAs (miRs) are small, 18-to-24 nucleotide noncoding RNAs that regulate stability and/or translation into protein of partially complementary target messenger RNA (mRNA) molecules.
- Are All Diseases Immunologic?January 01, 2010 | Nelson Chao, MD, MBA
Even if you are not an immunologist, it does appear that way. Take for example the metabolic syndrome, a group of symptoms that includes central obesity, high blood pressure, high triglycerides, insulin resistance, and low high-density lipoprotein (HDL).
- Handling Hemoglobin: Can Haptoglobin Mop Up Its Oxidative Threat?January 01, 2010 | Gregory M. Vercellotti, MD
The red blood cell packages hemoglobin and has evolved as the ideal oxygen delivery van. Its anti-oxidant environment, rich in glutathione, catalase, superoxide dismutase, etc., maintains iron in a reduced state to carry oxygen and prevents oxidation of globin and lipids.
- mTOR: A Target for Enhancing Memory T-Cell GenerationJanuary 01, 2010
Rapamycin, a natural bacterial product first found on Easter Island (Rapa Nui), was originally studied as an antifungal agent, but it was soon found to have potent anti-proliferative and immunosuppressive properties.
- Plasmacytoid Dendritic Cells in MyelomaJanuary 01, 2010 | Kenneth C. Anderson, MD
In this paper, Chauhan and colleagues from Dana-Farber Cancer Center used both
models of multiple myeloma (MM) cells and
murine xenograft models of human MM to define the role of plasmacytoid dendritic cells (pDCs) in the pathogenesis of MM. Immunohistochemical and phenotypic analysis demonstrates more frequent pDCs in MM patients than normal bone marrow (BM) and more pDCs in patient BM than peripheral blood (PB).
- Platelets and the Forces That Bind ThemJanuary 01, 2010 | Pete Lollar, MD
In 1687, Isaac Newton postulated that during fluid flow parallel to a solid surface, fluid velocity increases proportionately with distance from the surface.
- Targeting the Resistance in CMLJanuary 01, 2010 | Steven Grant, MD
Chronic myelogenous leukemia (CML) and acute promyelocytic leukemia (APL) represent prototypical diseases whose courses have been dramatically changed by the development of targeted forms of therapy.
- The Long and Winding Road Takes an Unexpected TurnJanuary 01, 2010 | Charles Parker, MD, Editor-in-Chief
Although type I interferons (INFα and INFβ) have been used therapeutically for three decades and have been tested against a variety of solid tumors and hematologic malignancies, overall, their clinical value has been modest.
- The Old Kid on the Block: Revisiting PEG-Interferon-Alpha for Chronic Myeloproliferative NeoplasmsJanuary 01, 2010 | Jason Gotlib, MD, MS
Those of us entering hematology training in the late 1990s witnessed the transition of interferon-α (IFN-α) therapy to life-support.